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Abstract
Background: Chronic kidney disease (CKD) affects approximately 15% of adults in the USA. As CKD progresses, urinary
phosphate excretion decreases and results in phosphate retention and, eventually, hyperphosphatemia. As hyperphosphatemia is associated with numerous adverse outcomes,
including increased cardiovascular mortality, reduction in
phosphorus concentrations is a guideline-recommended,
established clinical practice. Dietary phosphate restriction,
dialysis, and phosphate binders are currently the only options for phosphate management. However, many patients
with hyperphosphatemia have phosphorus concentrations
>5.5 mg/dL, despite treatment. Summary: This review pre
sents recent advances in the understanding of intestinal
phosphate absorption and therapeutic implications. Dietary
phosphate is absorbed in the intestine through two distinct
pathways, paracellular absorption and transcellular transport. Recent evidence indicates that the paracellular route
accounts for 65–80% of total phosphate absorbed. Thus, the
paracellular pathway is the dominant mechanism of phos-
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phate absorption. Tenapanor is a first-in-class, non-phosphate binder that inhibits the sodium-hydrogen exchanger
3 or solute carrier family 9 member 3 (SLC9A3) encoded by
the SLC9A3 gene, and blocks paracellular phosphate absorption. Key Messages: Targeted inhibition of sodium-hydrogen exchanger 3 effectively reduces paracellular permeability of phosphate. Novel therapies that target the paracellular pathway may improve phosphate control in chronic
kidney disease.
© 2021 The Author(s).
Published by S. Karger AG, Basel

Biological Role and Sources of Phosphate

Phosphorus is one of the most abundant minerals in
the body [1, 2]. Approximately 85% of total body phosphorus is skeletal and the remaining 15% is in soft tissues
[1]. Almost all of the phosphorus found in the extracellular fluid space is in the form of inorganic phosphate [1].
Proper functioning of many biological processes, including cellular energy production, release of oxygen to the
peripheral tissue by red blood cells, and bone mineralization, requires normal phosphate concentrations [1]. Although orthophosphate primarily circulates in plasma as
H2PO42– and HPO4– (4:1 ratio) [1], a small proportion
forms complexes with calcium and magnesium ions [3].
Correspondence to:
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Laboratory measurement of orthophosphate is reported
as serum phosphorus [4], with a normal range of 2.5–4.5
mg/dL [5].
Dietary phosphate ingestion is the primary source of
phosphorus intake [6]. Plant-based phosphate is primarily in the form of phytate (6-fold dihydrogen phosphate
ester of inositol) and is concentrated in whole grain cereals and legumes [7, 8]. Because humans lack the enzyme
phytase, there is minimal to no phytate degradation in the
small intestine, accounting for the low bioavailability of
plant-based dietary phosphate [9]. Phytates are considered by some experts to be “anti-nutritional factors” due
to their ability to prevent absorption of minerals [10, 11],
and the phytase enzyme is sometimes added to processed
food products to increase the bioavailability of minerals
[12]. There is evidence to suggest that phosphate from
animal-based sources such as meat or fish may be more
bioavailable than phosphate from plant-based sources
[13]. In a 1-week study, a primarily plant-based diet led
to lower phosphorus concentrations than a primarily animal-based diet containing the same quantity of phosphate [13]. This may have been due to the lower bioavailability of phytate-bound phosphorus in comparison to
animal-based sources and/or the additional strain on the
kidney from higher availability of protein in meat-based
diets [13]. Therefore, the source of dietary phosphate (animal-based vs. plant-based) influences phosphorus management [13].
Modern food processing has significantly increased
the quantity of dietary phosphate intake. The inclusion of
processed foods is estimated to increase daily dietary
phosphorus intake by approximately 1,000 mg [14, 15].
However, as food manufacturers are not required to list
the quantity of phosphorus in their food additives, the
actual quantity of dietary phosphorus from food additives
may easily supersede the estimated intake of 1,000 mg
[16, 17]. In addition, food additives are mostly inorganic
phosphate, which are believed to be more readily and
completely absorbed in humans compared to organic
phosphates [14].
A conventional Western diet contains a significant
proportion of processed foods [15, 18], which often contain unknown quantities of phosphate additives [15, 19].
The normal daily phosphorus intake is estimated at
>2,500 mg [14, 20, 21]. This intake is >3-fold greater than
the recommended daily allowance of approximately 700
mg [22]. Consequently, although patients with end-stage
renal disease (ESRD) should adhere to low phosphorus
diets of <1,000 mg daily [23], numerous phosphate additives may lead to an intake of much greater quantities of

phosphorus than appreciated [14]. Phosphate excipients
(e.g., anhydrous calcium hydrogen phosphate) commonly accompany medications prescribed for dialysis-dependent chronic kidney disease (CKD) patients, and excipients may contribute 100–200 mg of phosphorus to the
daily load [24, 25]. Therefore, the daily phosphorus intake
may approach 2,500 mg. Of this quantity, approximately
60–80% would be absorbed by the gastrointestinal tract
[26].
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Phosphate Regulation and Negative Impact of
Hyperphosphatemia in CKD

CKD is estimated to affect 15% of adults in the USA
[27]. As CKD progresses, urinary phosphate excretion
decreases and phosphate retention occurs [28]. Phosphate homeostasis is regulated by 3 hormones: parathyroid hormone (PTH), fibroblast growth factor-23
(FGF23), and active vitamin D in the form of calcitriol
(1,25-dihydroxycholecalciferol) [29]. Calcitriol increases
active intestinal phosphate transport by increasing expression of the transporters PiT-2 and NaPi2b [30–32],
whereas PTH and FGF23 work to decrease phosphate
concentrations [29]. In the early stages of CKD, PTH and
FGF23 concentrations increase as compensatory mechanisms [33–35]. These mechanisms enhance renal phosphate excretion and decrease intestinal phosphate absorption to maintain serum phosphorus concentrations
within the normal range [33–35]. Vitamin D receptordependent decreases in intestinal transcellular phosphate
transport as a result of compensatory mechanisms have
been observed in animal models [35]. Phosphorus concentrations are stable in early CKD stages before increasing in later stages, but FGF23 and PTH increase steadily
and significantly as the disease progresses, suggesting that
these mechanisms are eventually insufficient to maintain
phosphate homeostasis [33]. Consequently, >80% of patients with ESRD require treatment for hyperphosphatemia [36].
Hyperphosphatemia is associated with several adverse
outcomes (e.g., vascular calcification, cardiovascular
(CVD) disease, and secondary hyperparathyroidism)
[37–39]. Phosphate retention is considered the initiating
and driving force of the mineral and endocrine disruptions that comprise CKD-mineral bone disorder [40], a
common complication in patients with CKD associated
with CV morbidity and mortality [41–43]. Phosphate retention also triggers an increase in FGF23 and PTH concentrations, both of which have been suggested to have
523

Fig. 1. Dietary phosphorus absorption occurs in the small intestine via 2 distinct
pathways: transcellular and paracellular.
The transcellular pathway is characterized
by active intestinal phosphate transport
that occurs primarily through the action of
the NaPi2b. Maximum absorption via the
transcellular pathway is achieved at luminal phosphorus concentrations of approximately 6.0 mg/dL (2 mmol/L). Paracellular
phosphate absorption occurs passively
along concentration gradients through
tight junction complexes (e.g., claudins
and occludins) between cell membranes.
The mechanism of the paracellular phosphate absorption is consistent with nonsaturable, passive diffusion, which constitutes
the majority of intestinal phosphorus absorption in humans. NaPi2b, sodium-dependent phosphate cotransporter 2b.

direct pathogenic CV effects [44, 45]. Hyperphosphatemia is also an independent risk factor for CV mortality,
the primary cause of death in patients with CKD [27, 46,
47]. Kestenbaum et al. [48] found that each 1 mg/dL increase in serum phosphorus was associated with ∼23%
increased mortality risk. Phosphorus concentrations of
4.5–4.9 mg/dL were associated with greater hazard ratios
than concentrations of 4–4.5 mg/dL (1.93 vs. 1.34) [48].
Phosphorus concentrations greater than 3.5 mg/dL have
also been shown to increase mortality risk in both adults
with and without CKD [48, 49], confirming that even increases within normal concentrations (2.5–4.5 mg/dL)
negatively impact health outcomes. Improved patient
survival is associated with serum phosphorus concentrations that do not exceed 4.5 mg/dL [50].
Because of the negative consequences of hyperphosphatemia, reduction in phosphorus, with the goal of maintaining concentrations toward the normal range, is a guidelinerecommended, established clinical practice [23, 51]. However, achieving proper phosphorus control remains a
clinical challenge, and many patients with CKD have phosphorus concentrations exceeding 5.5 mg/dL [52]. The development of strategies and treatments guided by an understanding of the pathogenesis of hyperphosphatemia
and underlying physiology of phosphate absorption can
potentially improve our ability to manage phosphorus
concentrations and improve clinical outcomes.
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Advances in Phosphate Absorption and Regulation
Mechanisms

Serum phosphorus concentrations are balanced through
intestinal uptake, retention or by release from bone, and
regulation of renal phosphate reabsorption [53–55]. Phosphate from dietary sources travels through the gut and becomes available for intestinal absorption [55].
Dietary phosphate absorption occurs in the small intestine via 2 distinct pathways: the saturable transcellular pathway involving specific phosphate transporters
and the nonsaturable paracellular pathway driven by the
phosphate concentration gradient (Fig. 1) [55–58]. Classically, the transcellular pathway was considered the primary mechanism of phosphate absorption [53]. Animal
studies of the transcellular pathway document that active intestinal phosphate transport occurs primarily via
the sodium-dependent phosphate cotransporter 2b
(NaPi2b) [59]. Maximum absorption via the transcellular pathway is achieved at luminal concentrations of approximately 6.0 mg/dL phosphorus (2 mmol/L) in patients with ESRD [58]. Based on published data describing gastric volume, a typical Western diet containing
2,500 mg of phosphorus per day would produce luminal
phosphorus concentrations of approximately 55–110
mg/dL (18–36 mmol/L) [6, 14, 60], which greatly exceeds the transport maximum of the transcellular pathway. Experimental evidence from ESRD patients sugYee/Rosenbaum/Jacobs/Sprague

gests that NaPi2b is more important for phosphate absorption when luminal phosphate concentrations are
low [58], as might occur during dietary privation. The
minor role for transcellular absorption in humans is
supported by divergent results from NaPi2b inhibitor
trials in animals and humans. In animal trials, serum
phosphorus concentrations were reduced, consistent
with the hypothesis that transcellular transport was the
prime mediator of intestinal phosphate absorption [61].
These studies are often performed with diets that favor
the transcellular pathway and are not reflective of human phosphorus consumption. In humans, a phase 1
trial of a NaPi2b inhibitor found no changes in phosphorus concentrations of healthy volunteers or hyperphosphatemic patients with ESRD who were administered single (10 or 100 mg) or multiple (10, 30, or 100
mg 3 times per day) doses [62]. The transcellular pathway is not the primary modality of intestinal phosphate
absorption in humans [62, 63].
Human and animal models have shown that paracellular phosphate absorption occurs passively along concentration gradients through tight junction complexes
(e.g., claudins and occludins) between cell membranes
[58, 64–66]. The human concentration gradient is subject
to dietary intake and the bioavailability of phosphate
sources [58, 67]. Under normal dietary conditions, human and animal models have established that the paracellular route is nonsaturable and responsible for the majority of intestinal phosphate absorption, particularly when
phosphate concentrations are high [58, 64]. Animal models indicate that paracellular absorption constitutes about
65–80% of intestinal phosphate absorption and transcellular absorption is 20–35% [68, 69]. Because of the relatively high luminal phosphate concentrations associated
with modern diets and the lack of a saturation “limit,” the
paracellular route is responsible for a much greater proportion of phosphate absorption than the transcellular
route [58, 65].
Intestinal epithelial permeability of phosphate through
the paracellular pathway appears to be influenced by the
sodium-hydrogen exchanger 3 (NHE3), which is expressed throughout the human gastrointestinal tract and
more highly expressed in the small intestine [66, 70].
Regulation of NHE3 is achieved both acutely and chronically [71]. In animal and in vitro models of human small
intestinal enteroids, NHE3 inhibition increases transepithelial electrical resistance [66]. In the absence of an obvious signaling pathway or tight junction protein trafficking, the rapid increase in transepithelial electrical
resistance suggests that a direct pH-sensitive conformaSmall Intestinal Phosphate Absorption

tional change to the tight junction proteins (e.g., claudins) reduces paracellular phosphate permeability [66].
The effects of NHE3 inhibition were evaluated in NHE3knockout mice, created by disrupting the solute carrier
family 9 member 3 gene [72–74], and in animal trials of
a targeted NHE3 inhibitor [75]. These studies uniformly demonstrated reduced intestinal phosphate, sodium,
and water absorption [72–75]. These results have subsequently been confirmed in clinical trials of an NHE3 inhibitor in healthy volunteers and patients with ESRD. In
both groups, a dose-dependent inhibition of intestinal
phosphorus absorption was evident, resulting in decreased serum phosphorus in patients with ESRD [66,
76, 77]. Collectively, the paracellular phosphate absorption pathway is diminished by enterocyte inhibition of
NHE3.
Challenges of Current Phosphate Management in
Patients with CKD

Phosphorus management for patients with CKD currently consists of a three-pronged approach: restricting
dietary phosphate intake, reducing intestinal phosphate
absorption with phosphate binders, and enhancing phosphate elimination with dialysis [78]. A conventional hemodialysis session can remove up to 1,000 mg of phosphorus [79]. The efficacy of dialysis is limited by the small
amount of phosphate present in the readily accessible
plasma space [80]. Following removal of plasma phosphate, further removal is regulated by the rate-limiting
step of phosphate translocation from the intracellular
pool to plasma [80]. While dietary phosphate restriction
and phosphate removal by dialysis are important, these
maneuvers do not consistently achieve and/or maintain
appropriate phosphorus control [81]. For hemodialysis
patients with persistent hyperphosphatemia, there is lowquality evidence that monthly dietary therapy represents
effective therapy [82].
Controlling serum phosphorus through dietary interventions (low phosphorus diet) is a key component of
hyperphosphatemia management but brings challenges
with adherence as well as maintaining adequate nutrition.
For example, there is a strong correlation between dietary
phosphate and protein intake [83]. As a corollary, dietary
phosphate restriction may place patients at risk for inadequate protein intake [84]. Patients with advanced CKD
are at substantial risk for malnutrition, characterized by
protein-energy wasting and low energy intake, that increases risk of morbidity and mortality [85, 86].
Am J Nephrol 2021;52:522–530
DOI: 10.1159/000518110

525

Fig. 2. Tenapanor, a specific, investigational NHE3 inhibitor, produces a modest intracellular proton retention

that is proposed to induce conformational change(s) in claudin proteins present in tight junctions, thereby reducing paracellular phosphate transport. NHE3, sodium-hydrogen exchanger 3.

Phosphate binders are prescribed to >80% of patients
on dialysis and are the only pharmacological treatment
currently indicated for hyperphosphatemia [36]. These
agents form complex dietary phosphates in the intestinal
lumen and form insoluble complexes that are excreted
[87–91]. However, the administration of phosphate
binders as a class generally does not achieve and maintain phosphorus concentrations <5.5 mg/dL [92]. The
mechanism of action of phosphate binders is inherently
inefficient and provides a potential explanation for the
challenges that patients and clinicians face in achieving
target serum phosphorus concentrations. Nonspecific
binding to ligands other than phosphate results in suboptimal efficacy and drug-drug interactions with medications commonly prescribed to patients on dialysis [87–
91, 93]. Also, the short duration of action of phosphate
binders require binders to be taken with meals and snacks
[87–91]. The limited per pill phosphate binding capacity
mandates the ingestion of multiple pills, many that are
large in size [26, 94–101]. Despite phosphate binder therapy, recent data demonstrate that 42% of patients on dialysis had phosphorus concentrations >5.5 mg/dL, 77%
were >4.5 mg/dL in the most recent month, and 77%
were unable to consistently maintain phosphorus concentrations <5.5 mg/dL over a 6-month period [92], reinforcing the notion that current therapies, even when
properly implemented, are insufficient to manage hyperphosphatemia.
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New Targeted Therapies for Hyperphosphatemia

Given the growing evidence that the principal mode of
small intestinal phosphate absorption takes place via the
paracellular pathway, new therapies targeting this pathway have been investigated. Tenapanor, an investigational, first-in-class non-phosphate absorption inhibitor, targets the paracellular pathway via inhibition of enteric
NHE3 (Fig. 2) [66]. In rodents and in experiments using
human stem cell-derived enteroid monolayers, inhibition
of NHE3 produces intracellular acidification. This change
in pH is proposed to produce a subsequent conformational change in tight junction proteins, such as claudins
or occludins, which limit paracellular phosphate transit
from lumen-to-plasma [66]. By interrupting phosphate
absorption, tenapanor directly and efficiently reduces serum phosphorus concentrations [77].
Tenapanor was initially approved for treatment of irritable bowel syndrome with constipation (IBS-C) in
2019, and trial safety data for this indication adds support to the safety data generated in patients with hyperphosphatemia. In phase 1 trials of healthy volunteers, reduced intestinal phosphate and sodium absorption and
enhanced intestinal fluid volume were documented
without deleterious effect on serum potassium concentrations [76, 102]. Likewise, there were no clinically significant alterations of serum sodium concentrations
from baseline in a phase 2 study of IBS-C [103]. Diarrhea
was the most common adverse event in the phase 2 (9%)
Yee/Rosenbaum/Jacobs/Sprague

and phase 3 IBS-C trials (16%) [103, 104]. Most cases of
diarrhea were transient and mild to moderate in severity
[103, 104].
Preclinical data from an animal model revealed that
tenapanor effectively reduced phosphate absorption and
facilitated a 50% reduction in phosphate binder dose
[105]. In clinical trials, tenapanor has been evaluated for
efficacy as monotherapy (vs. placebo) in separate trials of
12 and 52 weeks. At 12 weeks, tenapanor administration
lowered serum phosphorus in subjects from baseline concentrations of 8.1 mg/dL to 5.5 mg/dL in the efficacy analysis set [77]. This phase 3, double-blinded, placebo-controlled randomized trial of tenapanor showed no clinically significant changes of sodium or potassium
concentrations from baseline in patients on dialysis in the
USA. [77]. Diarrhea, the most common adverse event,
was observed in 30%, 41%, and 48% of subjects receiving
3 mg, 10 mg, and 30 mg of tenapanor, respectively [77].
Softened stool and a modest increase in bowel movement
frequency may be anticipated with tenapanor administration [77]. In the long-term phase 3 study, at 26 weeks,
tenapanor administration lowered serum phosphorus in
subjects from baseline concentrations of 7.7 mg/dL to 5.1
mg/dL in the efficacy analysis set [106].
Tenapanor has also been investigated with phosphate binders as part of a dual mechanism approach to
phosphorus lowering in a 4-week human study [107].
A significantly larger proportion of subjects treated
with tenapanor and binders achieved serum phosphorus concentrations of <5.5 mg/dL at week 1 (49% vs.
21%; p < 0.001), week 2 (41% vs. 24%; p = 0.003), week
3 (47% vs. 18%; p < 0.001), and week 4 (37% vs. 22%; p
= 0.01) compared to those who only received binders
[107]. An extension study evaluating the capacity of
tenapanor to reduce serum phosphorus to within the
normal range (<4.5 mg/dL) is ongoing (ClinicalTrials.
gov: NCT03988920).
Nicotinamide is another potential treatment of hyperphosphatemia. This compound appears to inhibit gut NaPi2b cotransporters, thereby reducing phosphate-specific
transcellular permeability [108]. Although intestinal NaPi2b-mediated cotransport of sodium and phosphate is
responsible for >90% of transcellular or active phosphate
absorption in rats [59], the bulk of human phosphate absorption is passively mediated by the nonsaturable paracellular route [58]. Consequently, one could surmise that
nicotinamide would be less efficacious than tenapanor as
a treatment of hyperphosphatemia due to its lack of effect
on paracellular phosphate absorption. This hypothesis is
supported by the lack of significant reductions in phos-

phorus or FGF23 in nondialysis CKD patients treated by
lanthanum carbonate and/or nicotinamide during a
12-month trial [109].
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Future Studies

Novel strategies that minimize the detrimental effects
of hyperphosphatemia must also be explored in parallel.
For example, it is possible that the harmful effects of high
phosphorus concentrations are attributable to abnormalities in phosphate-sensing mechanisms [110]. Therefore,
a greater understanding of phosphate regulatory and
sensing mechanisms may provide insights into future
methodologies that reduce the harmful effects of phosphorus overload [110].
Conclusion

Hyperphosphatemia in patients with CKD and ESRD
remains a clinical challenge. Current therapeutic options
are inadequate. Treatment choices beyond the dietary restriction of phosphate and phosphate binding are urgently needed. Innovations that directly inhibit phosphate absorption represent an advancement over conventional
intestinal phosphate-binding strategies. Lowering paracellular phosphate absorption via intestinal NHE3 inhibition represents a novel mechanism that may have a greater quantitative effect on lowering serum phosphorus concentrations. Concomitant with a primary strategy of
blocking phosphate absorption via the paracellular pathway, phosphate binders may be considered adjunctive
therapy. Additional clinical trials in patients with CKD
and ESRD assessing the efficacy of hyperphosphatemia
treatments using both surrogate and hard patient-centered outcomes would be beneficial.
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